# CG Oncology, Inc. (CGON)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4.25B  
**Price:** $54.92 (-3.09%)

> CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—as well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4M | — | -$191M | -$161M | — |
| 2024 | $1M | — | -$115M | -$88M | — |
| 2023 | $204,000 | — | -$55M | -$49M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $792M | $39M | $753M | $32M | $3M |
| 2024 | $755M | $21M | $733M | $257M | — |
| 2023 | $199M | $15M | -$123M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$132M | $134,000 | -$132M |
| 2024 | -$79M | $234,000 | -$79M |
| 2023 | -$46M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/CGON)